April 19, 2022 – The U.S. Preventive Services Task Force seeks comments on a draft recommendation statement and draft evidence review on hormone therapy for the primary prevention of chronic conditions in postmenopausal persons. Based on its review of the evidence, the Task Force recommends against the use of hormone therapy, either estrogen alone or a combination of estrogen and progestin, to prevent chronic health problems in people who have gone through menopause. The draft recommendation statement and draft evidence review are available for review and public comment from April 19, 2022, to May 16, 2022 here.
